Salvia Investment GmbH has disclosed a significant ownership stake in Bambusa Therapeutics, Inc., as detailed in a recent SEC filing. This move is noteworthy as it underscores Salvia's strategic investment in the biotechnology industry, particularly in biological products.

According to the filing dated October 29, 2026, Salvia Investment now holds approximately 4,119,600 shares of common stock in Bambusa Therapeutics. Additionally, the company has various holdings in preferred stock, including Series Seed, Series A-1, and Series A-2 preferred stocks, amounting to over 4.6 million shares of common stock when converted.

Background

Salvia Investment GmbH is a non-U.S. entity based in Holzkirchen, Bavaria, Germany. The company is classified under the SIC description of "Other" and does not have a public trading presence. The recent SEC filing, accession number 0002162499-26-000002, reflects Salvia's recent activity, with this being the only filing recorded on October 29, 2026.

What the Filing Says

The filing indicates that Salvia Investment is a ten-percent owner of Bambusa Therapeutics, Inc. The document states:

"Salvia Investment GmbH now owns 4,119,600 shares of common stock following the transaction."

Additionally, Salvia holds:

  • 3,135,066 shares of Series Seed Preferred Stock
  • 1,473,775 shares of Series A-1 Preferred Stock
  • 160,860 shares of Series A-2 Preferred Stock

All preferred stocks will automatically convert to common stock prior to Bambusa's initial public offering.

Impact

This significant stake may affect various stakeholders, including current shareholders of Bambusa Therapeutics and potential investors looking at the biotech sector. Salvia's investment reflects confidence in Bambusa's future and the broader market for biological products, which is increasingly competitive.

What's Next

The filing does not say what happens next. However, the substantial investment by Salvia Investment may lead to further developments or strategic initiatives within Bambusa Therapeutics as it prepares for its initial public offering.